Fair Value Calculator Fair Value Calculator
EN DE

REXNORD (REXNORD) Fair Value & Analysis

IN · Market cap ₹1.1B

R REXNORD REXNORD · BSE
Price₹83.95
Fair Value₹74.18
Upside-11.6%
Quality52/100
Watch REXNORD for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹55.63 – ₹92.72

Fair value as of: Jul 6, 2026

From 24 valuation models · updated today

Share price +8.5% over the past month.

Price vs Fair Value (12 months)

₹102.57 ₹49.80 Fair Value ₹74.18 Jul 2025 Jul 2026

12‑month range ₹49.80 – ₹102.57 · fair‑value band ₹55.63 – ₹92.72 · the ₹83.95 price screens above the ₹74.18 fair value. As of Jul 6, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

REXNORD (REXNORD) currently trades at ₹83.95, while our model-based Fair Value estimate is ₹74.18 — implying the stock looks roughly 11.6% overvalued today. We read business quality at 52/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, REXNORD generated revenue of ₹1.2B at a net margin of 4.1%. Revenue grew 7.5% year over year. It earns a return on equity of 5.2%. Net debt stands at ₹38.7M. Fundamentals as of Jul 6, 2026

Our scenario range runs from ₹55.63 (bear case) to ₹92.72 (bull case); at ₹83.95, the current price sits within that range. The share trades about 20% below its 52-week high and 86% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹1.2B
Revenue growth (YoY) +7.5%
Net margin 4.1%
Return on equity 5.2%
Free cash flow ₹81.6M FY2025
P/E ratio 22.6
More key figures
Operating margin 20.3%
EPS (TTM) ₹3.71
EPS growth (YoY) +344%
Net debt ₹38.7M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

REXNORD reported revenue of ₹1.2B in FY2025 versus ₹711M in FY2021, a compound +13.4%/yr. Reported net income was ₹49.2M in FY2025, compounding −14.3%/yr from FY2021.

Revenue +13.4%/yr
FY21 ₹711M
FY22 ₹885M
FY23 ₹963M
FY24 ₹1.1B
FY25 ₹1.2B
Net income −14.3%/yr
FY21 ₹91.2M
FY22 ₹63.5M
FY23 ₹74.3M
FY24 ₹49.9M
FY25 ₹49.2M

Is REXNORD fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "REXNORD Fair Value". https://www.fairvalue-calculator.com/stock/REXNORD

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is REXNORD (REXNORD) undervalued?
As of Jul 6, 2026, our model estimates a fair value of ₹74.18 versus a price of ₹83.95 — about −12% (overvalued). Model-based estimate, not financial advice.
What is the fair value of REXNORD?
Our model-based fair value for REXNORD is ₹74.18 (as of Jul 6, 2026), built from audited fundamentals. The current price is ₹83.95.
What is the quality score of REXNORD?
REXNORD has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of REXNORD (REXNORD)?
REXNORD reported trailing-twelve-month revenue of about ₹1.2B (latest available figure, as of Jul 6, 2026).
What is the net profit margin of REXNORD?
The net profit margin of REXNORD is about 4.1%, meaning it keeps roughly 4.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.